Novocure Ltd reports results for the quarter ended in March - Earnings Summary

NovoCure

02/05/2024 20:41

* Novocure Ltd  NVCR.OQ  reported a quarterly adjusted loss
of 36
cents​​ per share for the quarter ended in March, higher than
the same quarter last year, when the company reported EPS of -50
cents.  The mean expectation of seven analysts for the quarter
was for a loss of 42 cents per share. Wall Street expected
results to range from -52 cents to -36 cents per share.
    * Revenue rose 13.4% to $138.50 million from a year ago;
analysts
expected $131.45 million. 
    * Novocure Ltd's reported EPS for the quarter was a loss
of 36
cents​.
    * The company reported a quarterly loss of $38.76 million.
    * Novocure Ltd shares had fallen by 18.5% this quarter and
lost 14.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 10.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for Novocure Ltd is
$25.00 
This summary was machine generated from LSEG data May 2 at 07:41
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.42          -0.36          Beat
 Dec. 31 2023      -0.52          -0.45          Beat
 Sep. 30 2023      -0.52          -0.46          Beat
 Jun. 30 2023      -0.50          -0.54          Missed